These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 31409187)
1. A Latent Class Approach to Modeling Trajectories of Health Care Cost in Pediatric Cystic Fibrosis. Levy JF; Rosenberg MA Med Decis Making; 2019 Jul; 39(5):593-604. PubMed ID: 31409187 [No Abstract] [Full Text] [Related]
2. Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012. Jackson AD; Jackson AL; Fletcher G; Doyle G; Harrington M; Zhou S; Cullinane F; Gallagher C; McKone E Pharmacoeconomics; 2017 Oct; 35(10):1087-1101. PubMed ID: 28699086 [TBL] [Abstract][Full Text] [Related]
3. Bayesian nonparametric latent class model for longitudinal data. Koo W; Kim H Stat Methods Med Res; 2020 Nov; 29(11):3381-3395. PubMed ID: 32536251 [TBL] [Abstract][Full Text] [Related]
5. Cost of care of patients with cystic fibrosis in The Netherlands in 1990-1. Wildhagen MF; Verheij JB; Verzijl JG; Hilderink HB; Kooij L; Tijmstra T; ten Kate LP; Gerritsen J; Bakker W; Habbema JD Thorax; 1996 Mar; 51(3):298-301. PubMed ID: 8779135 [TBL] [Abstract][Full Text] [Related]
6. Understanding the costs of care for cystic fibrosis: an analysis by age and health state. van Gool K; Norman R; Delatycki MB; Hall J; Massie J Value Health; 2013; 16(2):345-55. PubMed ID: 23538187 [TBL] [Abstract][Full Text] [Related]
7. Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Sims EJ; Mugford M; Clark A; Aitken D; McCormick J; Mehta G; Mehta A; Lancet; 2007 Apr; 369(9568):1187-95. PubMed ID: 17416263 [TBL] [Abstract][Full Text] [Related]
8. Integrating latent classes in the Bayesian shared parameter joint model of longitudinal and survival outcomes. Andrinopoulou ER; Nasserinejad K; Szczesniak R; Rizopoulos D Stat Methods Med Res; 2020 Nov; 29(11):3294-3307. PubMed ID: 32438854 [TBL] [Abstract][Full Text] [Related]
9. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Lieu TA; Ray GT; Farmer G; Shay GF Pediatrics; 1999 Jun; 103(6):e72. PubMed ID: 10353969 [TBL] [Abstract][Full Text] [Related]
10. A Bayesian latent class model for predicting gestational age in health administrative data. Wang S; Puggioni G; Wen X Pharm Stat; 2022 Nov; 21(6):1199-1218. PubMed ID: 35535938 [TBL] [Abstract][Full Text] [Related]
11. Prenatal screening for cystic fibrosis: an economic analysis. Nielsen R; Gyrd-Hansen D Health Econ; 2002 Jun; 11(4):285-99. PubMed ID: 12007162 [TBL] [Abstract][Full Text] [Related]
12. Identifying developmental trajectories of body mass index in childhood using latent class growth (mixture) modelling: associations with dietary, sedentary and physical activity behaviors: a longitudinal study. Koning M; Hoekstra T; de Jong E; Visscher TL; Seidell JC; Renders CM BMC Public Health; 2016 Oct; 16(1):1128. PubMed ID: 27793201 [TBL] [Abstract][Full Text] [Related]
13. Assessing the cost of cystic fibrosis diagnosis and treatment. Rosenberg MA; Farrell PM J Pediatr; 2005 Sep; 147(3 Suppl):S101-5. PubMed ID: 16202771 [TBL] [Abstract][Full Text] [Related]
14. Short-term persistence of high health care costs in a nationally representative sample of children. Liptak GS; Shone LP; Auinger P; Dick AW; Ryan SA; Szilagyi PG Pediatrics; 2006 Oct; 118(4):e1001-9. PubMed ID: 17015496 [TBL] [Abstract][Full Text] [Related]
15. Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. Angelis A; Kanavos P; López-Bastida J; Linertová R; Nicod E; Serrano-Aguilar P; BMC Health Serv Res; 2015 Sep; 15():428. PubMed ID: 26416027 [TBL] [Abstract][Full Text] [Related]
16. Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. Chevreul K; Michel M; Brigham KB; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Schieppati A; Iskrov G; Péntek M; von der Schulenburg JM; Kanavos P; Persson U; Fattore G; Eur J Health Econ; 2016 Apr; 17 Suppl 1():7-18. PubMed ID: 27059622 [TBL] [Abstract][Full Text] [Related]
17. Predictive modeling of total healthcare costs using pharmacy claims data: a comparison of alternative econometric cost modeling techniques. Powers CA; Meyer CM; Roebuck MC; Vaziri B Med Care; 2005 Nov; 43(11):1065-72. PubMed ID: 16224298 [TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616 [TBL] [Abstract][Full Text] [Related]
19. [A short-term diagnostic and economic impact model of neonatal screening for cystic fibrosis]. Rasch A; Perleth M Klin Padiatr; 2011 Mar; 223(2):96-103. PubMed ID: 21305445 [TBL] [Abstract][Full Text] [Related]
20. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Robson M; Abbott J; Webb K; Dodd M; Walsworth-Bell J Thorax; 1992 Sep; 47(9):684-9. PubMed ID: 1440461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]